Research shows that while European consumers are getting drug prices up to a third below U.S. levels, their nations are paying a cost by losing research and development jobs to countries where better profits are being made. Price controls and slow approval processes are viewed by drug companies as hurting Europe's ability to compete with the U.S., and in the long term, the study shows, Europe will pay an economic price for lower drug prices.
Financial Times (London), April 28
Research shows that while European consumers are getting drug prices up to a third below U.S. levels, their nations are paying a cost by losing research and development jobs to countries where better profits are being made. Price controls and slow approval processes are viewed by drug companies as hurting Europe's ability to compete with the U.S., and in the long term, the study shows, Europe will pay an economic price for lower drug prices.
Financial Times (London), April 28
[Editor's note: and think of the price they'll pay in the form of drugs they won't have, ones that some fleeing researchers might have created but might now never research, produce, and use to help patients, if anyone cares about that.]
